P
PLIANT THERAPEUTICS INC
NASDAQ: PLRX (Pliant Therapeutics, Inc.)
Last update: 11 hours ago1.39
-0.06 (-4.14%)
| Previous Close | 1.45 |
| Open | 1.45 |
| Volume | 834,426 |
| Avg. Volume (3M) | 1,154,935 |
| Market Cap | 85,326,960 |
| Price / Sales | 3.07 |
| Price / Book | 0.320 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 |
| Diluted EPS (TTM) | -3.61 |
| Total Debt/Equity (MRQ) | 23.40% |
| Current Ratio (MRQ) | 11.03 |
| Operating Cash Flow (TTM) | -174.10 M |
| Levered Free Cash Flow (TTM) | -112.84 M |
| Return on Assets (TTM) | -33.89% |
| Return on Equity (TTM) | -63.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Pliant Therapeutics, Inc. | Mixed | Bearish |
AIStockmoo Score
0.8
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.83 |
|
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 3.04% |
| % Held by Institutions | 101.02% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Cormorant Asset Management, Lp | 31 Mar 2025 | 3,000,000 |
| Trv Gp Iv, Llc | 31 Mar 2025 | 2,132,867 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 27 Jun 2025 | Announcement | Pliant Therapeutics Provides Update on BEACON-IPF |
| 21 May 2025 | Announcement | Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference |
| 08 May 2025 | Announcement | Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results |
| 01 May 2025 | Announcement | Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |